Redo-mitral valve replacement in adult patients had a 12% in-hospital mortality and 72% 5-year survival, with worse survival associated with LVEF <50%, concomitant AVR, and urgent surgery.
Observational (n=49)
No
What are the clinical outcomes and survival rates in adult patients undergoing redo-mitral valve replacement?
Redo-mitral valve replacement carries a 12% in-hospital mortality and reasonable mid-term survival, though outcomes are significantly worse in patients with LVEF < 50%, concomitant aortic valve replacement, or urgent surgery.
The aim of this study was to investigate the overall outcome of adult patients undergoing redo-mitral valve replacement (redo-MVR) at our institution. Forty-nine patients (24 males) underwent redo-MVR with either bioprosthetic (n = 24) or mechanical valves (n = 25) between January 2000 and 2010. Median age of patients was 63 years (range 21-80 years), and the mean additive EuroSCORE was 12 ± 4. Median time to re-operation was 8.2 ± 6.6 years for first time redo-MVR and 6.4 ± 5.6 years for second-time redo-MVR. Indications included prosthetic endocarditis (n = 22), para-prosthetic leak (n = 12), structural valve degeneration (n = 8), prosthetic valve thrombosis (n = 6) and malignancy (n = 1). The mean follow-up was 47.5 ± 37.0 months (range 0.1-112.3 months). In-hospital mortality was 12% (n = 6). Mean hospital stay was 17 ± 11 days (range 8-50 days). Actuarial survival at 1 and 5 years was 81 ± 5% and 72 ± 6%, respectively. Three patients required re-intervention: two for prosthetic valve endocarditis and one for para-prosthetic leak. Multivariate analysis showed that overall survival was associated with the LVEF < 50% (P < 0.001), concomitant AVR (P < 0.001) and urgent surgery (P = 0.03).
Vohra et al. (Tue,) conducted a observational in Redo-mitral valve replacement (n=49). Redo-mitral valve replacement was evaluated on In-hospital mortality. Redo-mitral valve replacement in adult patients had a 12% in-hospital mortality and 72% 5-year survival, with worse survival associated with LVEF <50%, concomitant AVR, and urgent surgery.